Table 2.
Univariate analyses for overall, cancer-specific, and disease-free survivals in advanced UTUC patients.
| Overall Survival | Cancer-Specific Survival | Disease-Free Survival | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | p-Value | HR | 95% CI | p-Value | HR | 95% CI | p-Value |
| Adjuvant chemotherapy | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.636 | 0.478–0.847 | 0.002 * | 0.700 | 0.495–0.990 | 0.044 * | 0.624 | 0.459–0.850 | 0.003 * |
| Chemotherapy regimens | |||||||||
| Gemcitabine and cisplatin | 1 | 1 | 1 | ||||||
| MVAC | 1.014 | 0.598–1.718 | 0.960 | 0.847 | 0.475–1.511 | 0.574 | 0.794 | 0.480–1.316 | 0.371 |
| Carboplatin-based | 0.529 | 0.127–2.204 | 0.382 | 0.314 | 0.043–2.296 | 0.254 | 0.482 | 0.116–1.998 | 0.315 |
| Others | 1.215 | 0.774–1.905 | 0.397 | 1.048 | 0.640–1.714 | 0.853 | 1.057 | 0.689–1.624 | 0.799 |
| Sex | |||||||||
| Male | 1 | 1 | 1 | ||||||
| Female | 1.011 | 0.788–1.296 | 0.932 | 1.110 | 0.814–1.515 | 0.509 | 1.119 | 0.851–1.472 | 0.421 |
| Age | |||||||||
| <70 | 1 | 1 | 1 | ||||||
| ≥70 | 1.750 | 1.360–2.253 | <0.001 * | 1.407 | 1.031–1.921 | 0.031 * | 1.280 | 0.971–1.686 | 0.080 |
| BMI | |||||||||
| <24 | 1 | 1 | 1 | ||||||
| ≥24 | 0.896 | 0.647–1.241 | 0.509 | 0.989 | 0.678–1.444 | 0.956 | 0.990 | 0.698–1.402 | 0.953 |
| ASA | |||||||||
| 1 | 1 | 1 | 1 | ||||||
| >1 | 2.527 | 0.352–18.131 | 0.357 | 1.833 | 0.254–13.201 | 0.548 | 1.202 | 0.296–4.885 | 0.797 |
| ECOG | |||||||||
| 0 | 1 | 1 | 1 | ||||||
| ≥1 | 1.115 | 0.805–1.544 | 0.513 | 0.978 | 0.672–1.423 | 0.906 | 1.028 | 0.729–1.449 | 0.876 |
| Smoking | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 1.181 | 0.849–1.643 | 0.323 | 1.482 | 1.005–2.186 | 0.047 * | 1.368 | 0.968–1.934 | 0.076 |
| Hospitals | |||||||||
| Medical centers | 1 | 1 | 1 | ||||||
| Regional hospitals | 1.111 | 0.880–1.403 | 0.376 | 1.166 | 0.882–1.541 | 0.280 | 1.105 | 0.855–1.429 | 0.446 |
| Tumor location | |||||||||
| Renal pelvis | 1 | 1 | 1 | ||||||
| Ureter | 1.134 | 0.848–1.517 | 0.395 | 1.358 | 0.952–1.937 | 0.091 | 1.349 | 0.979–1.858 | 0.067 |
| Renal pelvis + ureter | 1.200 | 0.869–1.657 | 0.267 | 1.214 | 0.808–1.824 | 0.351 | 1.289 | 0.910–1.826 | 0.153 |
| Tumor size | |||||||||
| <3 cm | 1 | 1 | 1 | ||||||
| ≥3 cm | 1.478 | 1.082–2.018 | 0.014 * | 1.898 | 1.281–2.810 | 0.001 * | 1.607 | 1.154–2.240 | 0.005 * |
| Histological variants | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 1.185 | 0.828–1.694 | 0.353 | 1.355 | 0.890–2.063 | 0.156 | 1.105 | 0.754–1.620 | 0.609 |
| Tumor grade | |||||||||
| Low grade | 1 | 1 | 1 | ||||||
| High grade | 2.854 | 1.269–6.421 | 0.011 * | 5.804 | 1.438–23.414 | 0.013 * | 4.212 | 1.565–11.339 | 0.004 * |
| Multifocality | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 1.367 | 1.062–1.758 | 0.015 * | 1.407 | 1.029–1.924 | 0.033 * | 1.390 | 1.053–1.836 | 0.020 * |
| Concurrent CIS | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 1.122 | 0.751–1.676 | 0.575 | 1.125 | 0.696–1.817 | 0.632 | 0.959 | 0.626–1.469 | 0.847 |
| Lymphovascular invasion | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 1.476 | 1.139–1.914 | 0.003 * | 1.672 | 1.223–2.285 | 0.001 * | 1.305 | 0.988–1.725 | 0.061 |
| Pathological T stage | |||||||||
| pT3 | 1 | 1 | 1 | ||||||
| pT4 | 2.723 | 1.980–3.746 | <0.001 * | 3.120 | 2.124–4.583 | <0.001 * | 2.294 | 1.567–3.357 | <0.001 * |
| Pathological N stage | |||||||||
| pN0 + pNx | 1 | 1 | 1 | ||||||
| pN1 + pN2 | 0.474 | 0.313–0.718 | <0.001 * | 0.389 | 0.246–0.617 | <0.001 | 0.410 | 0.269–0.625 | <0.001 * |
* p < 0.05. HR—hazard ratio; CI—confidence interval.